KR102153763B1 - 옥사졸리딘-2-온-피리미딘 유도체 - Google Patents
옥사졸리딘-2-온-피리미딘 유도체 Download PDFInfo
- Publication number
- KR102153763B1 KR102153763B1 KR1020157011951A KR20157011951A KR102153763B1 KR 102153763 B1 KR102153763 B1 KR 102153763B1 KR 1020157011951 A KR1020157011951 A KR 1020157011951A KR 20157011951 A KR20157011951 A KR 20157011951A KR 102153763 B1 KR102153763 B1 KR 102153763B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkoxy
- amino
- oxazolidin
- compound
- trifluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C(*)OC1=O)N1c1cc(-c2c(C(F)(F)F)nc(N)nc2)nc(N2C(*)COCC2)n1 Chemical compound *C(C(*)OC1=O)N1c1cc(-c2c(C(F)(F)F)nc(N)nc2)nc(N2C(*)COCC2)n1 0.000 description 1
- IFZVUYFUDJDCQD-MYCUJGIJSA-O CC(C)(C)[S+]([C@@](C)(c1ccccc1)OC[C@@H]([C@H](c(cc1)ccc1OC)O1)NC1=O)c1ccccc1 Chemical compound CC(C)(C)[S+]([C@@](C)(c1ccccc1)OC[C@@H]([C@H](c(cc1)ccc1OC)O1)NC1=O)c1ccccc1 IFZVUYFUDJDCQD-MYCUJGIJSA-O 0.000 description 1
- VLHZXGJXYNPHOT-VXKWHMMOSA-N CC(C)(C)[SiH-](C)(C)OCCCOc1ccc([C@@H]([C@H](CO[SiH-](C)(C)C(C)(C)C)N2)OC2=O)cc1 Chemical compound CC(C)(C)[SiH-](C)(C)OCCCOc1ccc([C@@H]([C@H](CO[SiH-](C)(C)C(C)(C)C)N2)OC2=O)cc1 VLHZXGJXYNPHOT-VXKWHMMOSA-N 0.000 description 1
- DUTDTRKNPVGIAC-IRXDYDNUSA-O CC(C)(CCOC[C@@H]([C@H](c(cc1)ccc1OCCOC)O1)NC1=O)[SiH+]C Chemical compound CC(C)(CCOC[C@@H]([C@H](c(cc1)ccc1OCCOC)O1)NC1=O)[SiH+]C DUTDTRKNPVGIAC-IRXDYDNUSA-O 0.000 description 1
- DTMSFEPLWGKINR-QWRGUYRKSA-N CC[C@@H]([C@H](c(cc1)ccc1OC)O1)NC1=O Chemical compound CC[C@@H]([C@H](c(cc1)ccc1OC)O1)NC1=O DTMSFEPLWGKINR-QWRGUYRKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725113P | 2012-11-12 | 2012-11-12 | |
| US61/725,113 | 2012-11-12 | ||
| PCT/IB2013/060052 WO2014072956A1 (en) | 2012-11-12 | 2013-11-11 | Oxazolidin-2-one-pyrimidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150082295A KR20150082295A (ko) | 2015-07-15 |
| KR102153763B1 true KR102153763B1 (ko) | 2020-09-09 |
Family
ID=49667527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157011951A Expired - Fee Related KR102153763B1 (ko) | 2012-11-12 | 2013-11-11 | 옥사졸리딘-2-온-피리미딘 유도체 |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI547493B (zh) | 2011-09-27 | 2016-09-01 | 諾華公司 | 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CA3037469C (en) * | 2015-09-24 | 2024-04-16 | Drexel University | Treatment of dermal disorders comprising a mtorc1 inhibitor |
| WO2017198347A1 (en) * | 2016-05-18 | 2017-11-23 | Piqur Therapeutics Ag | Treatment of skin lesions |
| CN109414415B (zh) | 2016-05-18 | 2023-05-02 | 拓客股份有限公司 | 皮肤病变的治疗 |
| TW201929861A (zh) | 2017-11-06 | 2019-08-01 | 瑞士商諾華公司 | 包含㗁唑啶-2-酮-嘧啶衍生物之調配物 |
| WO2019101853A1 (en) | 2017-11-23 | 2019-05-31 | Piqur Therapeutics Ag | Treatment of skin disorders |
| IL301285A (en) | 2020-09-10 | 2023-05-01 | Precirix N V | Antibody fragment against fap |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| JP2025517625A (ja) | 2022-05-02 | 2025-06-10 | プレシリックス・ナームローゼ・ベンノートシヤープ | プレターゲティング |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002496A1 (en) | 2002-03-15 | 2004-01-01 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| US20040009974A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| WO2007084786A1 (en) | 2006-01-20 | 2007-07-26 | Novartis Ag | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
| JPS4921149B1 (enExample) | 1970-12-28 | 1974-05-30 | ||
| JPS4921148B1 (enExample) | 1970-12-28 | 1974-05-30 | ||
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| DE69120221T2 (de) | 1990-07-03 | 1996-11-21 | Mitsui Petrochemical Ind | Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz |
| HUP9603433A3 (en) | 1995-04-13 | 1998-04-28 | Taiho Pharmaceutical Co Ltd | 4-6-diaryl-pyrimidine-derivatives, process for producing them and pharmaceutical compositions containing them |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| CA2297326C (en) | 1997-07-24 | 2007-03-20 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active component |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| PT930302E (pt) | 1998-01-16 | 2003-07-31 | Hoffmann La Roche | Derivados de benzo-sulfona |
| CN1312807A (zh) | 1998-06-19 | 2001-09-12 | 希龙公司 | 糖元合成酶激酶3的抑制剂 |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| EP1144390A2 (en) | 1999-01-22 | 2001-10-17 | Amgen Inc., | Kinase inhibitors |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| WO2001000207A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6498165B1 (en) | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| JP2003503354A (ja) | 1999-06-30 | 2003-01-28 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害剤化合物 |
| JP2003505384A (ja) | 1999-07-15 | 2003-02-12 | ファーマコピーア，インコーポレーティッド | ブラジキニンｂ１受容体アンタゴニスト |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| JP2003532635A (ja) | 2000-02-17 | 2003-11-05 | アムジエン・インコーポレーテツド | キナーゼ阻害薬 |
| IL151946A0 (en) | 2000-03-29 | 2003-04-10 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| WO2002068415A1 (en) | 2000-12-21 | 2002-09-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US20030130264A1 (en) | 2001-02-16 | 2003-07-10 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| WO2002096876A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| EP1397142A4 (en) | 2001-06-19 | 2004-11-03 | Bristol Myers Squibb Co | PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7 |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| ATE365733T1 (de) | 2002-03-15 | 2007-07-15 | Vertex Pharma | Zusammensetzungen brauchbar als protein-kinase- inhibitoren |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| JP2006515274A (ja) | 2002-10-08 | 2006-05-25 | マサチューセッツ・インスティテュート・オブ・テクノロジー | コレステロール輸送の調節のための化合物 |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| MXPA05005477A (es) | 2002-11-21 | 2005-07-25 | Chiron Corp | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer. |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP1608622A4 (en) | 2003-03-24 | 2009-04-01 | Merck & Co Inc | BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| US7763627B2 (en) | 2003-04-09 | 2010-07-27 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| WO2005009977A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| JP2007534624A (ja) | 2003-07-16 | 2007-11-29 | ニューロジェン・コーポレーション | ビアリールピペラジニル−ピリジン類縁体 |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| US7560464B2 (en) | 2004-04-13 | 2009-07-14 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| MX2007006230A (es) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| CN101080228A (zh) | 2004-12-13 | 2007-11-28 | 神经能质公司 | 哌嗪基－吡啶类似物 |
| WO2006071538A2 (en) | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Substituted biaryl analogues |
| JP5124285B2 (ja) | 2004-12-28 | 2013-01-23 | キネックス ファーマシューティカルズ， エルエルシー | 細胞増殖性障害を処置する組成物および方法 |
| AU2006206246A1 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| EP1877388A2 (en) | 2005-02-25 | 2008-01-16 | Kudos Pharmaceuticals Ltd | Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| US20110034454A1 (en) | 2006-01-11 | 2011-02-10 | Allan Paul Dishington | Morpholino pyrimidine derivatives and their use in therapy |
| EP2012794B1 (en) * | 2006-04-13 | 2014-09-17 | The Trustees of Columbia University in the City of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
| CL2007003847A1 (es) | 2006-12-28 | 2008-04-18 | Basf Ag | Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer. |
| US8173647B2 (en) | 2007-02-06 | 2012-05-08 | Gordana Atallah | PI 3-kinase inhibitors and methods of their use |
| US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2009066084A1 (en) | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| MX2010009743A (es) | 2008-03-05 | 2010-09-28 | Novartis Ag | Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami |
| EP2276488A1 (en) | 2008-03-26 | 2011-01-26 | Novartis AG | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| EP2280948A1 (en) | 2008-04-09 | 2011-02-09 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers. |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| US20110195966A1 (en) | 2008-10-31 | 2011-08-11 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| KR101677778B1 (ko) | 2009-02-06 | 2016-11-18 | 니뽄 신야쿠 가부시키가이샤 | 아미노피라진 유도체 및 의약 |
| JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
| MX346801B (es) | 2009-03-13 | 2017-03-31 | Agios Pharmaceuticals Inc | Métodos y composiciones para trastornos relacionados con la proliferación celular. |
| WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| PE20120325A1 (es) | 2009-05-19 | 2012-04-12 | Dow Agrosciences Llc | Aminopirimidinas sustituidas con arilo como agentes fungicidas |
| CA2987503C (en) | 2009-07-07 | 2019-02-26 | Mei Pharma, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| CN102625708A (zh) | 2009-09-09 | 2012-08-01 | 阿维拉制药公司 | Pi3激酶抑制剂及其用途 |
| WO2011072174A1 (en) | 2009-12-09 | 2011-06-16 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US20130184222A1 (en) | 2010-07-16 | 2013-07-18 | Agios Pharmaceuticals, Inc | Therapeutically active compositions and their methods of use |
| US9181215B2 (en) | 2010-10-01 | 2015-11-10 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
| HUE034637T2 (en) | 2010-10-18 | 2018-02-28 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods for mobilizing cholesterol |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| RU2013141559A (ru) | 2011-02-11 | 2015-03-20 | Дана-Фарбер Кэнсер Инститьют, Инк. | Способ ингибирования клеток опухоли гамартомы |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013030368A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| TWI547493B (zh) | 2011-09-27 | 2016-09-01 | 諾華公司 | 作為突變ｉｄｈ之抑制劑之３－嘧啶－４－基－唑啶－２－酮 |
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| HK1202435A1 (en) * | 2012-05-16 | 2015-10-02 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| KR20150017367A (ko) | 2012-06-06 | 2015-02-16 | 노파르티스 아게 | 종양 질환을 치료하기 위한 17-알파-히드록실라제 (c17,20-리아제) 억제제와 특이적 pi-3k 억제제의 조합물 |
| IN2015DN00528A (enExample) | 2012-08-16 | 2015-06-26 | Novartis Ag | |
| PT2912030T (pt) | 2012-10-23 | 2016-11-30 | Novartis Ag | Processo melhorado de fabrico de 5-(2,6-di-4-morfolinil-4- pirimidinil)-4-trifluorometilpiridin-2-amina |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| EA028122B1 (ru) | 2013-03-14 | 2017-10-31 | Новартис Аг | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2013
- 2013-11-01 US US14/069,400 patent/US9296733B2/en active Active
- 2013-11-07 UY UY0001035128A patent/UY35128A/es not_active Application Discontinuation
- 2013-11-08 AR ARP130104103A patent/AR093408A1/es unknown
- 2013-11-10 JO JOP/2013/0323A patent/JO3334B1/ar active
- 2013-11-11 AU AU2013343022A patent/AU2013343022B2/en not_active Ceased
- 2013-11-11 CU CU2015000050A patent/CU24365B1/es unknown
- 2013-11-11 CA CA2890942A patent/CA2890942C/en not_active Expired - Fee Related
- 2013-11-11 PE PE2015000615A patent/PE20151006A1/es active IP Right Grant
- 2013-11-11 EP EP17157570.7A patent/EP3199158B1/en active Active
- 2013-11-11 RS RS20170882A patent/RS56336B1/sr unknown
- 2013-11-11 SI SI201330782T patent/SI2922848T1/sl unknown
- 2013-11-11 HU HUE13795867A patent/HUE034492T2/en unknown
- 2013-11-11 CN CN201380052670.1A patent/CN104718204B/zh not_active Expired - Fee Related
- 2013-11-11 EP EP13795867.4A patent/EP2922848B1/en active Active
- 2013-11-11 PT PT137958674T patent/PT2922848T/pt unknown
- 2013-11-11 MA MA38076A patent/MA38076A1/fr unknown
- 2013-11-11 EA EA201790289A patent/EA029714B1/ru not_active IP Right Cessation
- 2013-11-11 MY MYPI2015701443A patent/MY174239A/en unknown
- 2013-11-11 AP AP2015008347A patent/AP2015008347A0/xx unknown
- 2013-11-11 ES ES13795867.4T patent/ES2641820T3/es active Active
- 2013-11-11 WO PCT/IB2013/060052 patent/WO2014072956A1/en not_active Ceased
- 2013-11-11 DK DK13795867.4T patent/DK2922848T5/en active
- 2013-11-11 TW TW102140929A patent/TWI608005B/zh not_active IP Right Cessation
- 2013-11-11 NZ NZ706591A patent/NZ706591A/en not_active IP Right Cessation
- 2013-11-11 JP JP2015541289A patent/JP6262245B2/ja not_active Expired - Fee Related
- 2013-11-11 PL PL13795867T patent/PL2922848T3/pl unknown
- 2013-11-11 HR HRP20171425TT patent/HRP20171425T1/hr unknown
- 2013-11-11 IN IN2912DEN2015 patent/IN2015DN02912A/en unknown
- 2013-11-11 KR KR1020157011951A patent/KR102153763B1/ko not_active Expired - Fee Related
- 2013-11-11 LT LTEP13795867.4T patent/LT2922848T/lt unknown
- 2013-11-11 BR BR112015010136A patent/BR112015010136A2/pt not_active Application Discontinuation
- 2013-11-11 MX MX2015005914A patent/MX363436B/es unknown
- 2013-11-11 SG SG11201503447QA patent/SG11201503447QA/en unknown
- 2013-11-11 EA EA201590929A patent/EA027987B1/ru not_active IP Right Cessation
- 2013-11-11 UA UAA201502809A patent/UA114001C2/uk unknown
-
2015
- 2015-03-27 TN TNP2015000120A patent/TN2015000120A1/fr unknown
- 2015-03-30 ZA ZA2015/02175A patent/ZA201502175B/en unknown
- 2015-04-12 IL IL238239A patent/IL238239A/en not_active IP Right Cessation
- 2015-05-06 CL CL2015001202A patent/CL2015001202A1/es unknown
- 2015-05-12 PH PH12015501053A patent/PH12015501053A1/en unknown
- 2015-05-12 CO CO15107787A patent/CO7380758A2/es unknown
- 2015-05-12 CR CR20150248A patent/CR20150248A/es unknown
- 2015-06-12 EC ECIEPI201525093A patent/ECSP15025093A/es unknown
-
2016
- 2016-02-18 US US15/047,574 patent/US10202371B2/en active Active
-
2017
- 2017-09-27 CY CY20171101014T patent/CY1119391T1/el unknown
-
2018
- 2018-12-18 US US16/224,212 patent/US20190382399A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040002496A1 (en) | 2002-03-15 | 2004-01-01 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| US20040009974A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| WO2007084786A1 (en) | 2006-01-20 | 2007-07-26 | Novartis Ag | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102153763B1 (ko) | 옥사졸리딘-2-온-피리미딘 유도체 | |
| US8865894B2 (en) | Oxazolidin-2-one compounds and uses thereof | |
| HK1236821A1 (en) | Oxazolidin-2-one-pyrimidine derivatives for use in the treatment of skin fibrosis, scleroderma, hypertrophic scars or keloids | |
| HK1236821B (en) | Oxazolidin-2-one-pyrimidine derivatives for use in the treatment of skin fibrosis, scleroderma, hypertrophic scars or keloids | |
| HK1209108B (en) | Oxazolidin-2-one-pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20230903 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20230903 |